The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.
This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.
Andreas Liebl is Medical Director of the Center for Diabetes and Metabolism at the Fachklinik in Bad Heilbrunn, Germany.
His research interests include insulin therapy, pharmacoeconomics, insulin pump therapy, intraperitoneal insulin therapy, continuous glucose monitoring and other diabetes technology. He is an advisor for the German Health Authorities and Payers Organisations. Dr. Liebl has been a board member of ‘Diabetes Technology – Insulin Pumps and Glucose Sensors’ AGDT, which is a working group of the German Diabetes Association (DDG).
He is also Past-Chairman and current board member of the Diabetes Expert Commission FKDB within the DDG. Dr. Liebl is author or co-author of more than 100 national and international publications and has delivered numerous presentations at scientific meetings all over the world.